ALS (motor neurone disease): who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• TDP-43 8
• SOD1 8
• C9orf72 4
• NRF2 0
• STING 0
• SIRT1 0
• HDAC 0
• NLRP3 0
• TREM2 0
• BDNF 0
• MAPK 0
• APOE 0
• GLP-1 0
• HMGB1 0
• mTOR 0
• SMN1 0
• TP53 0
• AMPK 0
• BTK 1
• CXCR4 0
• HSP90 1
• JAK 0
• JNK 0
• LAG-3 0
• NMDA 0
• PI3K 0
• PINK1 0
• PPAR 0
• TFEB 0
• TNF 0
• AKT 0
• APP 0
• ATM 0
• AXL 0
• BCL-2 0
• CDK4/6 0
• COX-2 0
• CSF1R 0
• ERK 0
• GPX4 0
• IL-1 0
• MAPT 0
• PARP 0
• PCSK9 0
• PDE4 1
• PSEN1 0
• PTEN 0
• SNCA 0
• STK11 0
• TLR4 0
• TTR 0
• VEGF 0
• YAP 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NINDS · F31

  Uncovering the Role of Perisynaptic Schwann Cells in C9ORF72 Amyotrophic Lateral Sclerosis Susceptibility and Progression

  University of Chicago· Chicago, United States· US$50,114 awarded in fiscal year 2026· until Sept 2029

• NIH NCI · F31

  Deciphering RNA Zipcodes: A Novel Framework for Subcellular Localization Element Annotation

  Baylor College of Medicine· Houston, United States· US$50,114 awarded in fiscal year 2026· until Sept 2029

• NIH NINDS · F31

  Nuclear-cytoskeletal coupling through the giant KASH protein ANC-1 maintains neuronal mechanical integrity during aging

  University of California at Davis· Davis, United States· US$43,471 awarded in fiscal year 2026· until Nov 2028

• NIH NIDCD · F31

  An articulatory brain-computer interface approach for restoring expressive communication to people with paralysis

  University of California at Davis· Davis, United States· US$43,752 awarded in fiscal year 2026· until Sept 2029

• NIH NINDS · R56

  Unraveling Mechanisms Governing Cell Clearance Deficits in C9ORF72-ALS/FTD

  University of Missouri-Columbia· Columbia, United States· US$539,427 awarded in fiscal year 2026· until Aug 2027

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Curation, Integration, Modelling and Rational Design of Small Molecule Amyloid Inhibitors (AmyStoppers)

  Vilniaus Universitetas· Vilnius, Lithuania· EU contribution €196,976· until Mar 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  From Stool to Solutions: Diagnose, Decode, Disruptors, and Deliver Interventions for the Human Gut Microbiota in Neurodegenerative Diseases. (GUT-4D)

  Universita Degli Studi del Piemonte Orientale Amedeo Avogadro· Vercelli, Italy· EU contribution €1,568,130· until Sept 2030· 8 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unraveling the impact of RNA-editing in neurodegeneration: a focus on TDP-43 related frontotemporal dementia. (NeuroEDIT)

  Asociacion Instituto de Investigacion Sanitaria Biogipuzkoa· Donostia-San Sebastian, Spain· EU contribution €194,075· until Aug 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  POLYMND: Polyamine dysregulation in Motor Neuron Disease as a targetable driver of astrocyte–neuron dysfunction

  The Chancellor Masters and Scholars of the University of Cambridge· Cambridge, United Kingdom· EU contribution €276,188· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Engineered Humanized Spinal Cord Construct for Advancing Health and Disease Research (SpineCraft)

  Fundacio Institut de Bioenginyeria de Catalunya· Barcelona, Spain· EU contribution €2,743,700· until Mar 2031

  The disease is named only in the funder's project summary, not in the title.

10 of 510 running projects, newest first. Listed amounts together: US$399.2m + €25.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 7
• Organoids 7
• Mendelian Randomization Analysis 18
• CRISPR-Cas Systems 8
• Gene Expression Profiling 24
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 6
• Exome Sequencing 6
• Proteomics 29
• Metabolomics 7
• Mass Spectrometry 6
• Flow Cytometry 2
• Immunohistochemistry 5
• Liquid Biopsy 2
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 57
• Machine Learning 18
• Deep Learning 7
• Cohort Studies 81
• Genome-Wide Association Study 24

• Optimized gGBE enables robust G-to-Y conversion in mammalian cells and zebrafish embryos.

  Zool Res, Nov 2026

• CRISPR/Cas9-based nanodelivery systems for precision gene editing in neuroinflammation.

  Inflamm Res, Oct 2026

• Parallel Analysis of Repeat Expansions: An Updated Clinical Nanopore Cas9-Targeted Sequencing Workflow for Nanopore R10 Flow Cells.

  J Mol Diagn, Sept 2026

• Deletion of exon 2 in ALS-linked Sptlc1 causes lethality in homozygous mice but not in heterozygotes.

  Life Sci Alliance, Jul 2026

• Targeting Non-Coding RNAs as a Potential Therapeutic and Delivery Strategy Against Neurodegenerative Diseases.

  Int J Mol Sci, Apr 2026

• Embedded CRISPRi Enhances Gene-Silencing Efficiency in Drosophila.

  Adv Sci (Weinh), Mar 2026

• Versatile CRISPR-Cas Tools for Gene Regulation in Zebrafish via an Enhanced Q Binary System.

  Adv Sci (Weinh), Feb 2026

• Development of a targeted BioPROTAC degrader selective for misfolded SOD1.

  Nat Commun, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.